GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CymaBay Therapeutics Inc (NAS:CBAY) » Definitions » Shiller PE Ratio

CymaBay Therapeutics (CymaBay Therapeutics) Shiller PE Ratio : (As of Jun. 04, 2024)


View and export this data going back to 2014. Start your Free Trial

What is CymaBay Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


CymaBay Therapeutics Shiller PE Ratio Historical Data

The historical data trend for CymaBay Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CymaBay Therapeutics Shiller PE Ratio Chart

CymaBay Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

CymaBay Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of CymaBay Therapeutics's Shiller PE Ratio

For the Biotechnology subindustry, CymaBay Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CymaBay Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CymaBay Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where CymaBay Therapeutics's Shiller PE Ratio falls into.



CymaBay Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

CymaBay Therapeutics's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, CymaBay Therapeutics's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.37/129.4194*129.4194
=-0.370

Current CPI (Dec. 2023) = 129.4194.

CymaBay Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -1.020 99.695 -1.324
201406 -0.560 100.560 -0.721
201409 -0.440 100.428 -0.567
201412 -0.930 99.070 -1.215
201503 -0.440 99.621 -0.572
201506 -0.090 100.684 -0.116
201509 -0.270 100.392 -0.348
201512 -0.270 99.792 -0.350
201603 -0.290 100.470 -0.374
201606 -0.300 101.688 -0.382
201609 -0.250 101.861 -0.318
201612 -0.300 101.863 -0.381
201703 -0.200 102.862 -0.252
201706 -0.310 103.349 -0.388
201709 -0.210 104.136 -0.261
201712 -0.080 104.011 -0.100
201803 -0.320 105.290 -0.393
201806 -0.300 106.317 -0.365
201809 -0.340 106.507 -0.413
201812 -0.330 105.998 -0.403
201903 -0.370 107.251 -0.446
201906 -0.350 108.070 -0.419
201909 -0.380 108.329 -0.454
201912 -0.430 108.420 -0.513
202003 -0.190 108.902 -0.226
202006 -0.160 108.767 -0.190
202009 -0.170 109.815 -0.200
202012 -0.230 109.897 -0.271
202103 -0.250 111.754 -0.290
202106 -0.340 114.631 -0.384
202109 -0.330 115.734 -0.369
202112 -0.350 117.630 -0.385
202203 -0.320 121.301 -0.341
202206 -0.310 125.017 -0.321
202209 -0.280 125.227 -0.289
202212 -0.300 125.222 -0.310
202303 -0.290 127.348 -0.295
202306 -0.010 128.729 -0.010
202309 -0.320 129.860 -0.319
202312 -0.370 129.419 -0.370

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


CymaBay Therapeutics  (NAS:CBAY) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


CymaBay Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of CymaBay Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


CymaBay Therapeutics (CymaBay Therapeutics) Business Description

Traded in Other Exchanges
Address
7575 Gateway Boulevard, Suite 110, Newark, CA, USA, 94560
CymaBay Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with liver and other chronic diseases with high unmet medical need. Its product in pipeline includes two clinical stage product candidates: seladelpar (a PPARd agonist) and MBX-2982 (a GPR119 agonist).
Executives
Charles Mcwherter officer: Chief Scientific Officer C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560
Daniel Menold officer: Vice President, Finance C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560
Paul T Quinlan officer: General Counsel C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560
Janet Dorling director C/O ACHAOGEN, INC., 1 TOWER PLACE, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Sujal Shah director, officer: Chief Executive Officer C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560
Kurt Von Emster director 601 GATEWAY BOULEVARD, SUITE 350, SAN FRANCISCO CA 94080
Harish Shantharam officer: Chief Financial Officer 7575 GATEWAY BLVD, NEWARK CA 94560
Dennis D Kim officer: Chief Medical Officer C/O EMERALD BIOSCIENCE, INC., 130 NORTH MARINA DRIVE, LONG BEACH CA 90803
Eric Lefebvre director C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, #200, SOUTH SAN FRANCISCO CA 94080
Thomas G Wiggans director
Lewis J Stuart officer: Chief Commercial Officer 3172 PORTER DRIVE, PALO ALTO CA 94304
Venbio Select Advisor Llc 10 percent owner 110 GREENE STREET, SUITE 800, NEW YORK NY 10012
Behzad Aghazadeh 10 percent owner C/O AVORO CAPITAL ADVISORS LLC, 110 GREENE STREET, SUITE 800, NEW YORK NY 10012
Carl Goldfischer director 161 WEST 61ST STREET, NEW YORK NY 10022
Robert James Wills director 175 TOYOTA PLAZA, 7TH FLOOR, MEMPHIS TN 38103